.

Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Cerilliant
Baxter
US Department of Justice
Covington
Chubb
Federal Trade Commission
McKesson
Chinese Patent Office

Generated: December 17, 2017

DrugPatentWatch Database Preview

Neos Theraps Company Profile

« Back to Dashboard

What is the competitive landscape for NEOS THERAPS, and what generic alternatives to NEOS THERAPS drugs are available?

NEOS THERAPS has three approved drugs.

There are six US patents protecting NEOS THERAPS drugs.

There are two patent family members on NEOS THERAPS drugs in two countries.

Summary for Neos Theraps

International Patents:2
US Patents:6
Tradenames:3
Ingredients:2
NDAs:3
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Neos Theraps IncCOTEMPLA XR-ODTmethylphenidateTABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL205489-003Jun 19, 2017RXYesNo► Subscribe► Subscribe► Subscribe
Neos Theraps IncCOTEMPLA XR-ODTmethylphenidateTABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL205489-002Jun 19, 2017RXYesNo► Subscribe► SubscribeY► Subscribe
Neos Theraps IncCOTEMPLA XR-ODTmethylphenidateTABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL205489-001Jun 19, 2017RXYesNo► Subscribe► Subscribe► Subscribe
Neos TherapsADZENYS XR-ODTamphetamineTABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL204326-005Jan 27, 2016RXYesNo► Subscribe► SubscribeY► Subscribe
Neos Theraps IncCOTEMPLA XR-ODTmethylphenidateTABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL205489-002Jun 19, 2017RXYesNo► Subscribe► Subscribe► Subscribe
Neos TherapsADZENYS XR-ODTamphetamineTABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL204326-006Jan 27, 2016RXYesYes► Subscribe► SubscribeY► Subscribe
Neos TherapsADZENYS XR-ODTamphetamineTABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL204326-006Jan 27, 2016RXYesYes► Subscribe► SubscribeY► Subscribe
Neos TherapsADZENYS XR-ODTamphetamineTABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL204326-006Jan 27, 2016RXYesYes► Subscribe► SubscribeY► Subscribe
Neos Theraps IncADZENYS ERamphetamineSUSPENSION, EXTENDED RELEASE;ORAL204325-001Sep 15, 2017RXYesYes► Subscribe► SubscribeY► Subscribe
Neos TherapsADZENYS XR-ODTamphetamineTABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL204326-003Jan 27, 2016RXYesNo► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Neos Theraps Drugs

Country Document Number Estimated Expiration
European Patent Office2726066► Subscribe
World Intellectual Property Organization (WIPO)2013003622► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
McKesson
Moodys
Teva
Johnson and Johnson
Daiichi Sankyo
Julphar
Cipla
QuintilesIMS
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot